Pharmaceutical composition for transnasal administration
AssigneesDaicel Corporation, National University Corporation Hokkaido University
InventorsSeiichi UCHIMURA, Shuji NAKATSUKA, Masahito KAWABORI
Life of this patent
Estimating the term…
Loading patent…
AssigneesDaicel Corporation, National University Corporation Hokkaido University
InventorsSeiichi UCHIMURA, Shuji NAKATSUKA, Masahito KAWABORI
Estimating the term…
The purpose of the present disclosure is to provide a pharmaceutical composition having an excellent therapeutic effect for the treatment of a central nervous system disease. The pharmaceutical composition for transnasal administration contains a purified extracellular vesicle product and is used for treating a central nervous system disease. The purified extracellular vesicle product is obtained by a method for producing a purified extracellular vesicle product, with the method including: (i) purifying a liquid to be treated and containing extracellular vesicles and an impurity by bringing the liquid into contact with an exclusion and anion exchange carrier to obtain a treated liquid containing the extracellular vesicles; and (ii) subjecting the treated liquid to membrane filtration to obtain a concentrate of the extracellular vesicles. The resulting pharmaceutical composition for transnasal administration exhibits an excellent therapeutic effect for the treatment of a central nervous system disease.
A pharmaceutical composition for transnasal administration, the pharmaceutical composition comprising a purified extracellular vesicle product and being used for treating a central nervous system disease,
A method for producing a pharmaceutical composition for transnasal administration for treating global cerebral ischemia, the production method comprising:
Dependencies are inferred from the claim text.